ReidAnn E. Sever

This paper develops and optimizes 111In-Dinutuximab-IRDye800, a dual-modality imaging agent for neuroblastoma resection, finding that an optimal dose and ratio maximize tumor detection.

This study shows that CD200 depletion in gliomas enhances antitumor immunity and leads to tumor rejection by modulating immune cell activity and cytokine expression.